When medetomidine—a potent veterinary sedative never approved for human use—began appearing in New York's illicit drug supply in May 2024, public health officials faced an urgent puzzle: How could they track an unknown threat and reach people in danger before it spread further?
The answer lay in an unglamorous but lifesaving infrastructure: drug-checking programs at 21 sites across New York State where community members could anonymously test their drugs and receive real-time results. Over the next eighteen months, epidemiologists, public health agencies, and harm reduction workers turned that data into a coordinated response that offers a blueprint for how modern surveillance can save lives.
A new study published in the New England Journal of Medicine Evidence, led by University at Albany biostatistician John Angles Ph.D. '26 alongside researchers at the New York State Department of Health and the New York City Department of Health and Mental Hygiene, documents both the danger and the response. What they found was a substance that spread with alarming speed. For several months after its initial detection, medetomidine showed up in fewer than 10 percent of opioid samples tested. Then, in October 2024, it surged to more than 20 percent. By May 2025, it had infiltrated 44 percent of all opioid samples tested statewide—a doubling in six months. By December 2025, it was detected in 30 percent of samples.
The danger was real. Medetomidine induces a state of sedation far deeper and more prolonged than typical opioids, and its risks don't end when a person stops using. Repeated exposure can trigger a severe withdrawal that requires intensive medical care. As Angles explained, "Tracking where medetomidine is appearing in the drug supply, and keeping the public and health providers informed, can enable effective interventions to reduce harm."
What distinguished New York's response was its speed and coordination. In June 2024, barely a month after detection, the State and City Departments of Health issued the first public alert, detailing what medetomidine was, how it appeared in drug samples, and harm reduction strategies. Subsequent alerts followed in December 2025 and January 2026, addressing clinical management of withdrawal and emphasizing that naloxone should always be administered in overdose situations. By January 2026, the state had distributed 15,000 medetomidine-specific test strips to nine partner organizations, including Catholic Charities and other harm reduction groups operating in the Capital Region and beyond.
The real innovation was making surveillance actionable. Technicians at the drug-checking sites tested samples and returned immediate results to users, providing real-time data that epidemiologists could analyze and act on. This close feedback loop meant that as medetomidine's prevalence changed, so did public health messaging. Alerts targeted not just the general public but specifically healthcare providers who needed to understand medetomidine's withdrawal profile.
The study underscores what can happen when communities, public health agencies, and data systems work in concert. New York didn't wait for deaths to mount before responding. It didn't rely on speculation or anecdote. Instead, it built a surveillance system that treated drug users as partners in public health—testing samples, receiving information, and having access to the tools they needed to protect themselves. In a landscape where drug supplies grow more unpredictable by the month, that collaborative, data-driven approach may be the most important public health innovation of our time.